Literature DB >> 3140456

Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages.

A J Crowle1, J A Sbarbaro, M H May.   

Abstract

Isoniazid (INH) is said to inhibit tubercle bacilli equally well in vivo and in vitro, and to be mycobactericidal. Ceforanide (CEF) can inhibit tubercle bacilli in vitro but has been found ineffective clinically. These two drugs were tested against virulent tubercle bacilli in cultured human macrophages (MP), partly to compare the results with clinical experience, and partly for a better understanding of antituberculosis activities of these drugs in human beings. INH had the same minimal inhibitory concentration (MIC) against tubercle bacilli in MP as in 7H9 broth cultures. It killed multiplying bacilli in MP but not nonmultiplying bacilli, even at 100 times MIC. It killed both multiplying and nonmultiplying bacilli in broth cultures. It interfered with its own effectiveness against intra-MP bacilli by preventing nonmultiplying bacilli from beginning to multiply and thus become susceptible to killing. These findings help explain why this demonstrably mycobactericidal drug produces relapses of tuberculosis when used alone. It was confirmed that CEF is able to inhibit growth in broth cultures (MIC = 10 micrograms/ml). However, it was not effective against either multiplying or nonmultiplying bacilli in MP at concentrations up to 50 micrograms/ml. These results with the drugs INH and CEF support the good record of correlation between the human MP model of tuberculosis and clinical experience in antituberculosis chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140456     DOI: 10.1016/0041-3879(88)90036-0

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  8 in total

1.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

2.  Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3.

Authors:  A J Crowle; M H May
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.

Authors:  J Dhillon; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis.

Authors:  D S Kumararatne; A S Pithie; P Drysdale; J S Gaston; R Kiessling; P B Iles; C J Ellis; J Innes; R Wise
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid.

Authors:  John E Conte; Jeffrey A Golden; Mari McQuitty; Juliana Kipps; Sheila Duncan; Elaine McKenna; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

6.  Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.

Authors:  Takemasa Takii; Yoshifumi Yamamoto; Taku Chiba; Chiyoji Abe; John T Belisle; Patrick J Brennan; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic.

Authors:  A J Crowle; R Dahl; E Ross; M H May
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

8.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.